Business Context and Reporting Period
Company: Prestige Brands Holdings, Inc. (Prestige Consumer Healthcare Inc.)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended December 31, 2006
Business Overview: The Company markets, sells, and distributes over-the-counter (OTC) drug, personal care, and household cleaning brands to mass merchandisers, drug stores, and supermarkets primarily in the U.S. and Canada. The Company operates as a holding company with no direct operations.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Dec 31, 2006 | Nine Months Ended Dec 31, 2006 |
|---|---|---|
| Total Revenues | $80,124 | $240,598 |
| Net Income | $10,643 | $27,683 |
| Diluted EPS | $0.21 | $0.55 |
| Gross Profit Margin | 54.1% | 52.5% |
| Operating Income | $24,534 | $72,049 |
| Net Cash from Operating Activities | N/A | $55,289 |
| Total Debt (Long-term + Current) | $471,238 | $471,238 |
| Cash and Cash Equivalents | $4,802 | $4,802 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 11.1% for the nine months ended Dec 31, 2006, compared to the prior year. This was driven primarily by the acquisitions of the Wartner brand (Sept 2006), Chore Boy (Oct 2005), and The Doctor's (Nov 2005). Excluding acquisitions, organic revenue growth was 2.6%.
- Profitability: Net income rose 22.2% for the nine-month period ($27.7M vs. $22.6M). Gross profit margin improved slightly to 52.5% from 52.4%, aided by lower distribution costs due to reduced oil prices and a shift toward higher-margin OTC products.
- Segment Performance:
- OTC Drug: Revenues increased 13.1% (nine months), driven by Wartner and The Doctor's brands.
- Household Cleaning: Revenues increased 14.2% (nine months), largely due to the Chore Boy acquisition.
- Personal Care: Revenues declined 11.5% (nine months) due to continued consumption declines in Cutex, Denorex, and Prell brands.
- Interest Expense: Net interest expense increased 11.2% to $29.7M for the nine-month period due to higher interest rates on variable-rate debt (average cost of funds rose from 7.1% to 8.1%).
- Debt Reduction: The Company repaid $27.4M of indebtedness during the nine-month period, reducing total outstanding debt to $471.2M from $498.6M at the start of the fiscal year.
Guidance, Outlook, Risks, and Unusual Items
- Acquisitions: The Company completed the acquisition of Wartner USA B.V. for approximately $35.1M (including contingent payments) in September 2006. The purchase price was funded by operating cash flows.
- Legal Proceedings:
- Securities Class Action: A consolidated putative securities class action lawsuit remains pending regarding the Company's IPO. The Court dismissed Exchange Act claims in July 2006, but class certification is pending. Management believes remaining claims are legally deficient.
- Similasan Litigation: Similasan Corporation sued the Company alleging trademark infringement and breach of confidentiality regarding Murine products. Management intends to vigorously defend.
- OraSure Technologies: OraSure sought a preliminary injunction to stop sales of Wartner products. The Court denied the motion in October and December 2006. OraSure has appealed, and the Company is seeking resolution via arbitration.
- Interest Rate Risk: The Company has significant variable-rate debt ($345.2M). A 1% increase in interest rates would increase pre-tax earnings impact by approximately $3.4M, though interest rate caps limit this exposure to $2.2M.
- Concentration Risk: Approximately 58.6% of nine-month sales were derived from four major brands. One customer accounted for 23.6% of sales for the nine-month period.
- Outlook: Management expects to continue financing operations through internally generated funds and borrowings. No specific forward-looking financial guidance was provided in this filing.
Investor Verification Checklist
- Acquisition Integration: Verify the revenue contribution and margin performance of the newly acquired Wartner brand post-acquisition.
- Personal Care Decline: Assess the trajectory of the Personal Care segment, which saw an 11.5% revenue decline, and management's strategy to redeploy marketing funds to OTC growth brands.
- Debt Covenants: Confirm continued compliance with financial covenants (leverage ratio < 5.0:1, interest coverage > 2.75:1) given the high debt load ($471M) and variable interest rates.
- Legal Exposure: Monitor the status of the OraSure arbitration and the Similasan trademark litigation, as adverse outcomes could impact key product lines.
- Customer Concentration: Evaluate the risk associated with one customer representing nearly 24% of sales and the potential impact of any changes in that customer's purchasing behavior.